Clinical aspects of functional dyspepsia and efficacy of ganaton (itopride hydrochloride)
Abstract
Aim of investigation. Studying of clinical pattern of functional dyspepsia (FD) and efficacy of ganaton (itopride hydrochloride) in its treatment.
Material and methods. Overall 509 patients with FD were investigated. Before and after 4-week course of ganaton (itopride hydrochloride) 50 mg tid, severity of clinical symptoms was estimated by 4-point system.
Results. High frequency of combination of FD to nausea, symptoms of gastroesophageal reflux disease (heartburn) and irritable bowel syndromes (meteorism, disorders of defecation) was marked. Application of ganaton promoted relief of complaints in 46,6% of patients, significant decrease of their severity – at 47,8%.
Conclusions. Ganaton is efficient agent in treatment of FD and concomitant functional disorders of gastro-intestinal tract.
About the Authors
V. T. IvashkinRussian Federation
A. A. Sheptulin
Russian Federation
A. S. Trukhmanov
Russian Federation
References
1. Ивашкин В.Т., Шептулин А.А., Баранская Е.К. и др. Рекомендации по обследованию и лечению больных с синдромом диспепсии. – М., 2000. – С. 1–7.
2. Agreus L., Svardsudd K., Nyren O. et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time // Gastroenterology. – 1995. – Vol. 109. – P. 671–680.
3. Amarapurkar D.N., Rank P. Randomized, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia // J. Indian Med. Assoc. – 2004. – Vol. 102. – P. 735–760.
4. Brogden R., Carmine A., Heel R. et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as antiemetic // Drugs. – 1982. – Vol. 24. – P. 360–400.
5. Caballero-Plasencia A.M., Sofos-Kantoyannis S., Valenzuela-Barraco M. et al. Irritable bowel syndrome in patients with dyspepsia: a community-based study in southern Europe // Eur. J. Gastroenterol. Hepatol. – 1999. – Vol. 11. – P. 517–522.
6. Corsetti M., Tack J. Mechanisms of functional dyspepsia and its relation to IBS // Irritable bowel syndrome. Diagnosis and treatment / Eds. M. Camilleri, M.C. Spiller. – London: W.B. Saunders, 2002. – P. 117–126.
7. Crean G.P., Holden R.J., Knill-Jones R.P. et al. A database on dyspepsia // Gut. – 1994. – Vol. 35. – P. 191–202.
8. Evans P.R., Bak Y.T., Shuter B. et al. Gastroparesis and small bowel dysmotility in irritable bowel syndrome // Dig. Dis. Sci. – 1997. – Vol. 42. – P. 2087–2093.
9. Ganaton Post Marketing Surveillance Study Group // Gastroenterology Today. – 2004. – Vol. 8. – P. 1–8.
10. Holtmann G., Talley N.J. Clinician’s manual on managing dyspepsia. – London: Life Science Communications, 2000. – 88 p.
11. Holtmann G., Talley N.J., Liebregts T. et al. A placebo-controlled trial of itopride in functional dyspepsia // N. Engl. J. Med. – 2006. – Vol. 354. – P. 832–840.
12. Hotz J. Das Reizmagen-Syndrom. Nicht-ulzerцse Dyspepsie (NUD). – Gastro-Liga. – Frankfurt (Main), 2000. – 55 s.
13. Kanath S. Comparative evaluation of the efficacy and tolerability of itopride and metaclopramide in patients with non-ulcer dyspepsia // JAMA India. – 2003. – Vol. 2. – P. 95–98.
14. Karamanolis G., Tack J. Promotility medications – now and in the future // Dig. Dis. – 2006. – Vol. 24. – P. 297–307.
15. Knill-Jones R.P. Geographical differences in the prevalence of dyspepsia // Scand. J. Gastroenterol. – 1991 – Vol. 26. (suppl. 182). – P. 17–24.
16. McQuaid K.R. Dyspepsia // Sleisenger and Fordtran’s gastrointestinal and liver disease / Eds. M. Feldman et al. – 7th ed. – Philadelphia–London–Toronto–Montreal–Sydney–Tokyo, 2002. – P. 102–118.
17. Moayyedi P., Soo S., Deeks J. et al. Systemic review: Antacids, H2-receptor antagonists, prokinetiks, bismuth and sucralfate therapy for non-ulcer dyspepsia // Aliment. Pharmacol. Ther. – 2003. – Vol. 17. – P. 1215–1227.
18. Perri F., Clemente R., Vesta V. et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying // Am. J. Gastroenterol. – 1998. – Vol. 93. – P. 2082–2088.
19. Peura D. Meeting expectations in FD: clinical and regulatory objectives. Clinician’s viewpoint // Functional dyspepsia: current evidence and cutting edge outcomes. – Abstract book. – Montreal, 2005. – P. 16–18.
20. Richter R. Stress and psychological and environment factors in functional dyspepsia // Scand. J. Gastroenterol. – 1991 – Vol. 26. (suppl. 182). – P. 40–46.
21. Sawant P., Das H.S., Desai N. et al. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia // JAPI. – 2004. – Vol. 52. – P. 626–628.
22. Stanghellini V., Tosetti C., Paternico A. et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia // Gastroenterology. – 1996. – Vol. 110. – P. 1036–1042.
23. Tack J. New therapeutic targets for FD: what, how and whom? // Functional dyspepsia: current evidence and cutting edge outcomes. – Abstract book. – Montreal, 2005. – P. 22–24.
24. Tack J., Talley N.J., Camilleri M. et al. Functional gastroduodenal disorders // Gastroenterology. – 2006. – Vol. 130. – P. 1466–1479.
25. Talley N.J., Zinsmeister A.R., Schleck C.D. et al. Dyspepsia and dyspepsia subgroups: a population-based study // Gastroenterology. – 1992. – Vol. 102. – P. 1259–1268.
26. Talley N.J. and the working team for functional gastroduodenal disorders. Functional gastroduodenal disorders // The functional gastrointestinal disorders. – Boston–N.-Y.–Toronto–London, 1994. – P. 71–113.
27. Talley N.J., Stanghellini V., Heading R.C. et al. Functional gastroduodenal disorders // Rome II. The Functional Gastrointestinal Disorders / Ed. D.A. Drossman. – 2nd ed. – Allen Press, 2000. – P. 299–350.
28. Tonini M., de Ponti F., di Nucci A., Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics // Aliment. Pharmacol. Ther. – 1999. – Vol. 13. – P. 1585–1591.
29. Tonini M., Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders // Gastrointestinal pharmacology and therapeutics / Eds. C. Scarpignato, F. di Mario. – Basel: Karger, 2006. – P. 96–113.
30. Trimble K.C., Farouk R., Pryde S.F. et al. Heightened visceral sensation in functional gastrointestinal disease is not site-specific. // Dig. Dis. Sci. – 1995. – Vol. 40. – P. 1607–1613.
31. Van Wijk H.J., Smout A.J., Akkermans L.M. Gastric emptying and dyspeptic symptoms in the irritable bowel syndrome // Scand. J. Gastroenterol. – 1992. – Vol. 27. – P. 99–102.
32. Veldhuyzen van Zanten S.J., Jones M.J., Verlinden M., Talley N.J. Efficacy of cisapride and domperidone in functional dyspepsia: a meta-analysis // Am. J. Gastroenterol. – 2001. – Vol. 96. – P. 689–696.
33. Whitehead W.E. Functional bowel disorders: are they independent diagnoses? // Neurogastroenterology / Ed. E. Corazziari. – Berlin: W. de Gruyter, 1996. – P. 65–74.
34. Zighelboim J., Talley N.J., Phillips S.F. et al. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism // Dig. Dis. Sci. – 1995. – Vol. 40. – P. 819–827.
Review
For citations:
Ivashkin V.T., Sheptulin A.A., Trukhmanov A.S. Clinical aspects of functional dyspepsia and efficacy of ganaton (itopride hydrochloride). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2009;19(6):17-22. (In Russ.)
Views:
28
Email this article 
